Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | MMP9 | P14780 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247731 | 0.97 | KMT2A (0.41) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL2244922 | 0.95 | EPHX2 (0.42) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL9811897 | 0.95 | EPHX2 (0.42) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL2254208 | 0.95 | EPHX2 (0.42) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL4621861 | 0.93 | KMT2A (0.44) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL5323996 | 0.93 | KMT2A (0.44) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL8647821 | 0.83 | BLM (0.48) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL29501687 | 0.81 | EPHX2 (0.53) | MMP2MMP9EPHX2LMNAFOLH1 | |
| SCHEMBL27980046 | 0.79 | KMT2A (0.37) | KMT2AALOX15BLMPMP22MMP2 | |
| SCHEMBL21167226 | 0.79 | TSHR (0.46) | KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216758-A1 | CANCER STARVATION THERAPY | SERBIG PHARMACEUTICALS CORP. | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216758-A1 | CANCER STARVATION THERAPY | TUFM, TFAM, GFM1 | KMT2A 1203/4885ALOX15 4363/4885BLM 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.